1. A patient with major depressive disorder has been stable on vortioxetine 20 mg once daily for eight months. Her psychiatrist adds bupropion 150 mg twice daily for residual fatigue and to support smoking cessation. Two weeks later she reports worsening nausea, headache, and dizziness. Which pharmacokinetic interaction explains her new symptoms, and what dose adjustment is required?
A) Bupropion induces CYP3A4, accelerating vortioxetine metabolism and reducing its plasma concentration; the patient's symptoms reflect loss of antidepressant effect from subtherapeutic vortioxetine levels, and the dose should be increased to 25 mg or 30 mg to compensate.
B) Bupropion inhibits CYP2C9, a secondary metabolic pathway for vortioxetine; this produces a modest 20% to 30% increase in vortioxetine exposure that falls within the therapeutic range and does not require dose adjustment, suggesting her symptoms are unrelated to the drug interaction.
C) Bupropion and vortioxetine compete for the same plasma protein binding sites; bupropion displaces vortioxetine from albumin, transiently increasing free vortioxetine concentrations and producing the symptoms; the interaction resolves spontaneously as a new protein-binding equilibrium is established without requiring dose adjustment.
D) Bupropion is a potent CYP2D6 inhibitor, and CYP2D6 is vortioxetine's primary metabolic enzyme; coadministration functionally converts the patient to a poor metabolizer, approximately doubling vortioxetine plasma concentrations and producing dose-related adverse effects; vortioxetine must be reduced to a maximum of 10 mg daily.
E) Bupropion inhibits P-glycoprotein efflux transporters in the blood-brain barrier, increasing vortioxetine CNS penetration without changing plasma concentrations; the symptoms reflect excessive central serotonergic activity rather than elevated plasma drug levels, and the management is to switch to a non-P-glycoprotein substrate antidepressant.
ANSWER: D
Rationale:
Bupropion is a potent inhibitor of CYP2D6, the primary enzyme responsible for vortioxetine metabolism. When bupropion is added to a stable vortioxetine regimen, it substantially impairs CYP2D6-mediated vortioxetine clearance, functionally converting the patient's metabolic phenotype from an extensive metabolizer to a poor metabolizer and approximately doubling vortioxetine plasma concentrations. The resulting elevated vortioxetine exposure produces dose-related adverse effects including nausea, headache, and dizziness — symptoms consistent with the drug's known adverse effect profile at higher concentrations. The prescribing information for vortioxetine specifies a dose reduction to a maximum of 10 mg daily when potent CYP2D6 inhibitors such as bupropion, fluoxetine, or paroxetine are coadministered. This interaction is particularly clinically relevant because bupropion is frequently combined with other antidepressants for augmentation strategies.
Option A: Option A is incorrect because bupropion does not induce CYP3A4; bupropion's principal pharmacokinetic interaction is CYP2D6 inhibition, not CYP3A4 induction, and the patient's symptoms — consistent with excess drug exposure — would be explained by increased rather than decreased vortioxetine levels.
Option B: Option B is incorrect because bupropion's primary CYP interaction is at CYP2D6, not CYP2C9; furthermore, CYP2D6 inhibition by bupropion does not produce a modest 20% to 30% increase but rather an approximately twofold increase in vortioxetine exposure, which is clinically significant and requires dose adjustment.
Option C: Option C is incorrect because protein binding displacement is rarely the mechanism of clinically significant drug interactions; even when displacement occurs transiently, the free drug is rapidly redistributed and metabolized, preventing sustained elevation of free drug concentrations; this mechanism does not account for the vortioxetine-bupropion interaction.
Option E: Option E is incorrect because the clinically relevant vortioxetine-bupropion interaction operates through CYP2D6 metabolic inhibition affecting plasma concentrations, not through P-glycoprotein efflux at the blood-brain barrier; this option fabricates a CNS-penetration mechanism that does not correspond to the established pharmacokinetic basis of this interaction.
2. A psychiatrist in Europe considers adding agomelatine to a patient already taking fluvoxamine for obsessive-compulsive disorder. A colleague warns that the combination is contraindicated. The psychiatrist asks whether the concern is serotonin syndrome — since both drugs have serotonergic properties — or a pharmacokinetic interaction. Which answer correctly identifies the basis of the contraindication and explains why the serotonin syndrome concern does or does not apply?
A) The contraindication is pharmacokinetic, not pharmacodynamic: fluvoxamine is a potent CYP1A2 inhibitor and agomelatine is a CYP1A2 substrate, so coadministration markedly increases agomelatine plasma concentrations; serotonin syndrome risk is not the basis because agomelatine has no monoamine transporter activity and does not raise synaptic serotonin through reuptake inhibition.
B) The contraindication is pharmacodynamic: both fluvoxamine and agomelatine inhibit SERT, and combining two SERT inhibitors substantially increases synaptic serotonin beyond what either drug produces alone, creating a high risk of serotonin syndrome through additive transporter blockade.
C) The contraindication is both pharmacokinetic and pharmacodynamic: fluvoxamine inhibits CYP1A2, raising agomelatine levels, and agomelatine's elevated 5-HT2C antagonism at supratherapeutic concentrations paradoxically activates rather than blocks 5-HT2C receptors, producing a serotonin syndrome variant driven by postsynaptic 5-HT2C overstimulation.
D) The contraindication is pharmacokinetic: fluvoxamine induces CYP1A2, accelerating agomelatine metabolism and reducing plasma concentrations to subtherapeutic levels; serotonin syndrome is not a concern, but the combination must be avoided because it renders agomelatine ineffective rather than toxic.
E) The contraindication is pharmacodynamic: fluvoxamine's potent 5-HT2A antagonism and agomelatine's 5-HT2C antagonism together produce complete blockade of all 5-HT2 receptor subtypes, eliminating the inhibitory serotonergic feedback that prevents hyperdopaminergic states and producing a dopamine toxicity syndrome rather than serotonin syndrome.
ANSWER: A
Rationale:
The contraindication between fluvoxamine and agomelatine is entirely pharmacokinetic. Fluvoxamine is a potent inhibitor of CYP1A2 — the primary enzyme responsible for agomelatine's hepatic metabolism — and coadministration markedly increases agomelatine plasma exposure by preventing its first-pass and systemic clearance. Because agomelatine already has a low and highly variable baseline bioavailability, a substantial increase in exposure from CYP1A2 inhibition produces unpredictably high plasma concentrations with increased hepatotoxicity risk and potential for dose-related adverse effects. Serotonin syndrome is not the pharmacodynamic basis of this contraindication because agomelatine has no activity at SERT, NET, or DAT — it does not inhibit monoamine reuptake and does not raise synaptic serotonin concentrations through transporter blockade. Serotonin syndrome requires sufficient serotonergic excess, typically produced by combining agents that raise synaptic 5-HT through reuptake inhibition, increased synthesis, or receptor agonism; agomelatine's mechanism does not contribute to this pathway.
Option B: Option B is incorrect because agomelatine does not inhibit SERT; it has no monoamine transporter activity, and describing it as a SERT inhibitor that combines additively with fluvoxamine's SERT inhibition is a fundamental pharmacological error that misidentifies agomelatine's mechanism.
Option C: Option C is incorrect because while the CYP1A2 inhibition component is correctly identified, the claim that supratherapeutic agomelatine concentrations paradoxically activate rather than block 5-HT2C receptors is pharmacologically unsupported; agomelatine is an antagonist at 5-HT2C and does not convert to an agonist at high concentrations, and 5-HT2C overstimulation is not a recognized mechanism of serotonin syndrome.
Option D: Option D is incorrect because fluvoxamine inhibits CYP1A2 rather than inducing it; enzyme inhibition raises agomelatine levels rather than lowering them, and the consequence is potential toxicity rather than therapeutic failure — confusing inhibition with induction reverses the pharmacokinetic direction of the interaction.
Option E: Option E is incorrect because combined 5-HT2A and 5-HT2C blockade does not produce a dopamine toxicity syndrome; while disinhibition of dopaminergic tone through 5-HT2C blockade is part of agomelatine's therapeutic mechanism, complete 5-HT2 blockade does not eliminate serotonergic feedback in a way that produces a recognized dopamine toxicity syndrome, and this option fabricates a pharmacodynamic mechanism without clinical or pharmacological basis.
3. A patient taking vilazodone 40 mg daily has been consistently taking her dose on an empty stomach, unaware of the food requirement. She develops a fungal nail infection and is started on itraconazole, a potent CYP3A4 inhibitor, for eight weeks. Her physician reviews her medications. Integrating both the food effect and the drug interaction, which statement best describes the net pharmacokinetic situation during itraconazole coadministration?
A) The two pharmacokinetic factors cancel each other out: the reduced bioavailability from fasted administration lowers vilazodone exposure, while itraconazole-mediated CYP3A4 inhibition raises it; the net result is plasma concentrations approximately equivalent to what would be expected with food and no CYP3A4 inhibitor, so no dose adjustment is needed.
B) The fasted-state bioavailability reduction is irrelevant once itraconazole is added, because CYP3A4 inhibition during systemic distribution increases the half-life of circulating vilazodone sufficiently to compensate for any reduction in absorbed fraction; monitoring is recommended but dose adjustment is not required.
C) The patient is receiving less vilazodone than intended because of the fasted-state bioavailability reduction, and itraconazole will now substantially increase plasma concentrations from that already-altered baseline by inhibiting CYP3A4-mediated vilazodone metabolism; the combination of these two factors requires both correcting the food administration and reducing the vilazodone dose to 20 mg daily during itraconazole coadministration.
D) Itraconazole inhibits intestinal CYP3A4 specifically, which increases vilazodone bioavailability by preventing first-pass intestinal metabolism; in a fasted patient this effect is magnified because gastric emptying is faster and more drug reaches the intestinal CYP3A4 before it is inhibited, resulting in higher peak concentrations than in a fed patient on the same combination.
E) The fasted-state bioavailability reduction of vilazodone is entirely a CYP3A4-mediated first-pass effect in the intestinal wall; since itraconazole inhibits intestinal CYP3A4, adding itraconazole effectively restores vilazodone bioavailability to its fed-state level, meaning no separate dose adjustment is needed beyond what would apply to a fed patient starting itraconazole.
ANSWER: C
Rationale:
This question requires integrating two independent pharmacokinetic mechanisms simultaneously. First, vilazodone taken in the fasted state has a bioavailability of approximately 47% rather than the approximately 72% achieved with food — meaning this patient has been receiving substantially less vilazodone exposure than intended at her prescribed dose. Second, itraconazole is a potent CYP3A4 inhibitor, and vilazodone is primarily metabolized by CYP3A4; adding itraconazole will substantially increase vilazodone plasma concentrations by impairing both first-pass and systemic CYP3A4-mediated metabolism. The net result is that the patient transitions from subtherapeutic baseline exposure toward potentially elevated concentrations as CYP3A4 inhibition is superimposed. The appropriate management integrates both factors: correct the administration error by ensuring food coadministration going forward, and apply the prescribing information's dose reduction recommendation of 20 mg daily during strong CYP3A4 inhibitor coadministration.
Option A: Option A is incorrect because the two pharmacokinetic factors do not simply cancel each other out; the food effect reduces absorbed drug through a bioavailability mechanism, while CYP3A4 inhibition increases the bioavailability and systemic exposure of what is absorbed — these are not symmetrical and do not produce equivalent net exposure to the intended fed-state concentration.
Option B: Option B is incorrect because CYP3A4 inhibition affects vilazodone metabolism rather than correcting an absorption deficit; extending systemic half-life does not compensate for reduced absorbed fraction, and the two pharmacokinetic phenomena operate through different mechanisms that cannot offset each other through a half-life adjustment.
Option D: Option D is incorrect because while intestinal CYP3A4 inhibition is a real component of how itraconazole increases drug bioavailability, the claim that fasting magnifies this effect by accelerating gastric emptying and increasing drug-enzyme contact time is an overinterpretation that does not reflect the established pharmacokinetic data for vilazodone's food interaction, which is related to overall absorption conditions rather than a specific intestinal CYP3A4 saturation effect.
Option E: Option E is incorrect because vilazodone's food-dependent bioavailability is not entirely explained by intestinal CYP3A4-mediated first-pass metabolism; the food effect involves broader absorption conditions, and itraconazole's CYP3A4 inhibition does not selectively restore the bioavailability to the fed-state level while leaving no residual interaction requiring management.
4. A patient who has taken trazodone 75 mg nightly for insomnia for two years abruptly stops the medication without tapering. Her physician reassures her that she is unlikely to experience the discontinuation syndrome that occurs with SSRIs. Applying the mechanistic basis of antidepressant discontinuation syndrome, which explanation best justifies this reassurance?
A) Trazodone does not cause discontinuation syndrome because its potent 5-HT2A antagonism maintains postsynaptic serotonin receptor density at normal levels throughout treatment; when the drug is stopped, receptor density is unchanged, and no compensatory upregulation-driven rebound occurs.
B) Trazodone does not cause discontinuation syndrome at any dose because it is not classified as a serotonin reuptake inhibitor; only drugs that carry the SSRI or SNRI designation in their FDA-approved labeling produce physiological adaptation capable of causing discontinuation syndrome.
C) Trazodone does not cause discontinuation syndrome because its long elimination half-life of approximately 72 hours provides a natural gradual taper after the last dose; plasma concentrations decline slowly enough that serotonergic receptors never experience the abrupt reduction in drug exposure that triggers discontinuation symptoms.
D) Trazodone does not cause discontinuation syndrome because histamine H1 receptor blockade, which is trazodone's dominant pharmacodynamic action at hypnotic doses, does not produce the type of physiological dependence associated with monoamine transporter inhibition; H1 antagonists are inherently non-dependence-producing agents.
E) At hypnotic doses of 50 to 150 mg, trazodone does not produce clinically meaningful SERT occupancy; without sustained transporter blockade, the presynaptic serotonergic adaptations that drive discontinuation syndrome — receptor downregulation and compensatory changes in serotonergic signaling — do not develop, so abrupt cessation does not trigger a withdrawal state.
ANSWER: E
Rationale:
Antidepressant discontinuation syndrome is produced by physiological adaptation to sustained monoamine transporter occupancy. When SERT (or NET) is continuously blocked, presynaptic autoreceptors and postsynaptic receptor populations undergo compensatory adaptations — including autoreceptor downregulation and changes in receptor sensitivity — that maintain homeostatic serotonergic signaling in the context of chronically elevated synaptic 5-HT. Abrupt removal of transporter blockade then unmasks these adaptations as a withdrawal state. At the low doses used for insomnia (50 to 150 mg), trazodone does not produce clinically meaningful SERT occupancy; its dominant pharmacodynamic actions at these doses are H1 antagonism and alpha-1 adrenergic blockade. Without sustained SERT inhibition, the presynaptic adaptations responsible for discontinuation syndrome do not occur, and abrupt cessation does not trigger the characteristic symptoms of dizziness, paresthesias, and flu-like syndrome. This is mechanistically distinct from agomelatine, which avoids discontinuation syndrome because it has no transporter activity whatsoever at any dose.
Option A: Option A is incorrect because while 5-HT2A antagonism is part of trazodone's profile, the absence of discontinuation syndrome at hypnotic doses is explained by inadequate SERT occupancy rather than by preserved receptor density through 5-HT2A blockade; postsynaptic receptor density maintenance from 5-HT2A antagonism is not the established mechanistic explanation.
Option B: Option B is incorrect because discontinuation syndrome is not restricted to drugs carrying the SSRI or SNRI designation in their labeling; it is a pharmacodynamic consequence of sustained monoamine transporter occupancy, and any drug with sufficient SERT activity — including trazodone at high antidepressant doses — can produce it; the regulatory label class does not determine physiological dependence potential.
Option C: Option C is incorrect because trazodone's elimination half-life is approximately 5 to 9 hours, not 72 hours; a 72-hour half-life is a substantial overestimate, and the absence of discontinuation syndrome at hypnotic doses is explained by insufficient SERT occupancy, not by a prolonged pharmacokinetic taper after the last dose.
Option D: Option D is incorrect because while H1 antagonism is trazodone's dominant action at hypnotic doses and H1 antagonists do not produce monoamine-type dependence, attributing the absence of discontinuation syndrome entirely to the nature of H1 blockade ignores the correct explanation — that SERT occupancy is insufficient at these doses to produce the transporter-mediated adaptations that drive the syndrome.
5. A pharmacology student notes that trazodone and nefazodone are both classified as SARIs and share the core mechanism of SERT inhibition combined with 5-HT2A antagonism. She asks why they have such different clinical profiles despite the same class designation. Which answer most accurately describes the pharmacological differences that account for their divergent clinical use?
A) Nefazodone has substantially more potent SERT inhibition than trazodone, producing higher synaptic serotonin levels that translate into superior antidepressant efficacy; trazodone's weaker SERT inhibition explains why it is relegated to hypnotic use, while nefazodone's stronger antidepressant effect justified its brief period of widespread use as a primary antidepressant.
B) Nefazodone lacks trazodone's prominent alpha-1 adrenergic blocking activity, giving it less sedation and orthostatic hypotension than trazodone; however, nefazodone produces severe idiosyncratic hepatotoxicity through its metabolite para-hydroxynefazodone and is a potent CYP3A4 inhibitor, adverse properties that trazodone does not share and that now severely restrict nefazodone's clinical use.
C) Trazodone and nefazodone are pharmacologically identical at the receptor level; their different clinical profiles are explained entirely by nefazodone's longer elimination half-life, which produces sustained 5-HT2A antagonism that trazodone's shorter half-life cannot maintain, making nefazodone more effective as an antidepressant but also more prone to accumulation-related toxicity.
D) Nefazodone has direct dopamine D2 receptor antagonism in addition to its SARI mechanism, which produces a distinct antipsychotic-augmenting property absent from trazodone; this D2 blockade also mediates its hepatotoxicity by activating dopaminergic signaling in hepatic stellate cells, a mechanism unrelated to CYP enzyme inhibition.
E) Trazodone has significant muscarinic receptor antagonism that nefazodone lacks; this anticholinergic activity produces trazodone's prominent sedation and is the pharmacological basis for its use as a hypnotic, while nefazodone's cleaner receptor profile without anticholinergic activity made it the preferred SARI for pure antidepressant use before its hepatotoxicity became apparent.
ANSWER: B
Rationale:
Despite sharing the SARI classification, trazodone and nefazodone differ in two pharmacologically important ways that explain their divergent clinical profiles. First, trazodone has prominent alpha-1 adrenergic receptor blocking activity; this produces sedation and orthostatic hypotension that limit its use as a daytime antidepressant at the required doses but make it highly effective as a bedtime hypnotic. Nefazodone lacks this prominent alpha-1 blocking activity, giving it a comparatively cleaner tolerability profile in terms of sedation and orthostatic effects — which was one of its claimed advantages over trazodone when it was in widespread use. Second, and critically, nefazodone causes severe idiosyncratic hepatotoxicity through its metabolite para-hydroxynefazodone inhibiting mitochondrial complex I, and it is a potent CYP3A4 inhibitor producing clinically significant interactions with statins, benzodiazepines, and other CYP3A4 substrates. Trazodone shares neither of these adverse properties. The hepatotoxicity risk and interaction burden are the primary reasons nefazodone's use is now rare despite its pharmacologically favorable sedation and REM sleep-preserving properties.
Option A: Option A is incorrect because trazodone and nefazodone have broadly comparable SERT inhibitory potency, and superior antidepressant efficacy from stronger SERT inhibition is not the established explanation for nefazodone's historical use; nefazodone was favored for its tolerability and sleep architecture advantages, not for SERT potency superiority over trazodone.
Option C: Option C is incorrect because trazodone and nefazodone are not pharmacologically identical at the receptor level — the alpha-1 adrenergic blocking activity difference is a genuine pharmacodynamic distinction — and elimination half-life differences are not the basis of their clinical divergence; the explanation ignores the hepatotoxicity and CYP3A4 inhibition that define nefazodone's risk profile.
Option D: Option D is incorrect because nefazodone does not have clinically significant dopamine D2 receptor antagonism, and D2 blockade has no established role in nefazodone's hepatotoxicity mechanism; the hepatotoxicity is produced by para-hydroxynefazodone inhibiting mitochondrial complex I, not by dopaminergic hepatic signaling.
Option E: Option E is incorrect because trazodone does not have significant muscarinic receptor antagonism; trazodone's sedation is produced by H1 antagonism and alpha-1 adrenergic blockade, not anticholinergic activity, and describing trazodone as having significant muscarinic blocking activity attributes an adverse effect profile it does not possess.
6. A 45-year-old man in Finland is prescribed agomelatine 25 mg at bedtime for major depressive disorder. He smokes 25 cigarettes per day. After six weeks at the correct dose and confirmed adherence, his depression shows minimal improvement. His physician considers increasing the dose but first reviews the pharmacokinetics. Which pharmacokinetic explanation best accounts for the inadequate response despite correct dosing?
A) Heavy smoking increases gastric acid secretion, which degrades agomelatine in the stomach before absorption; the acid-mediated degradation is proportional to the number of cigarettes smoked per day and cannot be overcome by dose increases alone without concurrent proton pump inhibitor therapy.
B) Nicotine directly inhibits MT1 and MT2 melatonin receptors in the suprachiasmatic nucleus, competitively blocking agomelatine's receptor-level action; the pharmacodynamic antagonism is sufficient at 25 cigarettes per day to prevent circadian resynchronization even when agomelatine plasma concentrations are adequate.
C) Smoking-related hypoxia reduces hepatic CYP1A2 expression because the enzyme requires adequate oxygen tension for catalytic activity; lower CYP1A2 activity in heavy smokers impairs agomelatine's first-pass metabolism and paradoxically increases, rather than decreases, plasma concentrations.
D) Cigarette smoke contains polycyclic aromatic hydrocarbons that are potent CYP1A2 inducers; because agomelatine is primarily metabolized by CYP1A2, heavy smoking substantially increases CYP1A2 activity and accelerates agomelatine metabolism, reducing plasma concentrations to potentially subtherapeutic levels despite correct dosing.
E) Smoking increases hepatic blood flow through catecholamine-mediated splanchnic vasoconstriction, reducing the time agomelatine spends in contact with hepatic CYP1A2 during first-pass transit; the faster transit reduces first-pass extraction and paradoxically increases agomelatine bioavailability, making the inadequate response unlikely to be pharmacokinetic in origin.
ANSWER: D
Rationale:
Cigarette smoke contains polycyclic aromatic hydrocarbons (PAHs), which are potent inducers of CYP1A2 through activation of the aryl hydrocarbon receptor (AhR). Because agomelatine is primarily metabolized by CYP1A2, heavy smokers have substantially elevated CYP1A2 activity that accelerates agomelatine's first-pass and systemic metabolism, reducing its plasma concentrations significantly below those achieved in non-smokers at the same nominal dose. This is explicitly noted in the agomelatine prescribing information and represents a clinically important pharmacokinetic consideration: patients who smoke heavily may not achieve therapeutic plasma concentrations at the standard dose of 25 mg, potentially requiring dose adjustment to 50 mg to achieve adequate drug exposure. This interaction also means that smoking cessation during agomelatine therapy would increase plasma concentrations — a clinically relevant change requiring monitoring for potential dose-related adverse effects as CYP1A2 induction is removed.
Option A: Option A is incorrect because agomelatine is not degraded by gastric acid in a clinically meaningful way; the food and timing requirements for agomelatine are pharmacodynamic (circadian alignment) and relate to absorption conditions, not to acid-mediated chemical degradation, and proton pump inhibitor therapy has no established role in managing agomelatine's clinical pharmacokinetics.
Option B: Option B is incorrect because nicotine does not directly antagonize MT1 and MT2 melatonin receptors; there is no established pharmacodynamic interaction between nicotine and agomelatine's receptor targets, and this option fabricates a receptor-level mechanism that has no pharmacological basis.
Option C: Option C is incorrect because smoking-related hypoxia does not reduce CYP1A2 activity; the PAH-mediated AhR activation from cigarette smoke is a transcriptional induction mechanism that increases CYP1A2 expression rather than decreasing it, and hypoxia-mediated enzyme suppression is not the established consequence of smoking on CYP1A2 activity.
Option E: Option E is incorrect because the mechanism described — faster hepatic transit reducing first-pass extraction — would increase bioavailability rather than decrease it, and this option incorrectly concludes that the inadequate response is unlikely to be pharmacokinetic, when in fact smoking-induced CYP1A2 induction reducing agomelatine levels is the most pharmacokinetically sound explanation for the clinical picture.
7. Two patients are both started on agomelatine 25 mg at bedtime. Patient 1 achieves excellent antidepressant response within four weeks. Patient 2 shows no improvement after six weeks on the same dose with confirmed adherence and correct bedtime administration. Both patients have normal liver function and are non-smokers taking no interacting medications. Applying agomelatine's pharmacokinetic profile, which explanation best accounts for this divergence in response at identical doses?
A) Agomelatine has an average oral bioavailability of only approximately 3% to 5% due to extensive first-pass hepatic metabolism, but individual bioavailability ranges up to approximately 80%; two patients on the same nominal dose may achieve plasma concentrations differing by more than tenfold, meaning Patient 2 may be achieving subtherapeutic plasma concentrations despite taking the correct dose correctly.
B) Agomelatine's response variability at identical doses is explained entirely by pharmacodynamic differences in MT1 and MT2 receptor density between individuals; receptor density is genetically determined and normally distributed in the population, with approximately 20% of patients having too few melatonin receptors to achieve therapeutic benefit regardless of plasma drug concentration.
C) The divergence in response reflects the delayed onset of agomelatine's CYP1A2 autoinduction; after four to six weeks of treatment, some patients develop significant CYP1A2 induction from agomelatine's own metabolites, accelerating its clearance and reducing plasma concentrations below the therapeutic threshold in metabolically susceptible individuals.
D) Agomelatine has a narrow therapeutic window defined by 5-HT2C receptor occupancy; Patient 1 has achieved the 60% to 70% receptor occupancy required for antidepressant response, while Patient 2, despite identical dosing, has achieved only 40% occupancy due to differences in receptor reserve between individuals — a pharmacodynamic variability that cannot be corrected by dose adjustment.
E) The response divergence is explained by circadian rhythm phase differences between the two patients; Patient 1 has a normal sleep phase that aligns with agomelatine's peak plasma concentration, while Patient 2 has advanced sleep phase syndrome that causes the drug's MT1/MT2 agonism to occur during the wrong circadian window, rendering it pharmacodynamically ineffective at the receptor level despite adequate plasma concentrations.
ANSWER: A
Rationale:
Agomelatine's extraordinary pharmacokinetic variability is the most pharmacologically sound explanation for divergent responses at identical doses in two otherwise similar patients. Its average oral bioavailability is only approximately 3% to 5% in the general population due to extensive first-pass hepatic metabolism — one of the lowest bioavailabilities among oral antidepressants. However, some individuals achieve bioavailabilities above 80%, apparently reflecting substantial inter-individual differences in CYP1A2 and CYP2C9 first-pass metabolic capacity. The practical consequence is that two patients taking the same 25 mg dose at bedtime may achieve plasma concentrations differing by more than tenfold: Patient 1 may be a high-bioavailability individual achieving robust drug exposure and therapeutic MT1/MT2 agonism, while Patient 2 may be a low-bioavailability individual with plasma concentrations well below the therapeutic threshold despite perfect adherence. This is why agomelatine's prescribing guidelines allow dose escalation to 50 mg when the 25 mg dose is inadequate — acknowledging that many patients require a higher nominal dose to achieve sufficient systemic exposure.
Option B: Option B is incorrect because MT1/MT2 receptor density variation as a pharmacodynamic explanation for non-response is not established as the primary basis of agomelatine's inter-patient response variability; the pharmacokinetic variability in bioavailability is well documented and provides a more directly supported mechanistic explanation.
Option C: Option C is incorrect because agomelatine does not induce CYP1A2 through autoinduction by its own metabolites; autoinduction is a mechanism associated with drugs such as carbamazepine and is not part of agomelatine's established pharmacokinetic profile.
Option D: Option D is incorrect because a specific 5-HT2C receptor occupancy threshold of 60% to 70% for antidepressant response and the concept of pharmacodynamic receptor reserve variability between individuals is not the established framework for agomelatine's response variability; the pharmacokinetic bioavailability explanation is more directly supported by the published pharmacology.
Option E: Option E is incorrect because while agomelatine's circadian mechanism makes the timing of administration important, advanced sleep phase syndrome preventing pharmacodynamic efficacy despite adequate plasma concentrations is not the primary explanation for inter-patient variability in antidepressant response at the same dose; bioavailability differences are the more pharmacokinetically grounded explanation.
8. Both vortioxetine and vilazodone produce gastrointestinal adverse effects that are among the most common reasons for early discontinuation. A clinician managing a patient who cannot tolerate GI side effects wants to understand the mechanistic difference between the two drugs' GI profiles in order to counsel the patient appropriately. Which statement most accurately distinguishes the GI adverse effect profiles of vortioxetine and vilazodone?
A) Vortioxetine and vilazodone produce identical GI adverse effects through the same mechanism — SERT inhibition in the enteric nervous system raising synaptic serotonin and activating 5-HT3 receptors on enterochromaffin cells — and can be expected to cause GI adverse effects of equivalent type and severity in the same patient.
B) Vortioxetine produces constipation as its primary GI adverse effect because its 5-HT3 antagonism in the gut reduces the serotonin-mediated pro-motility signaling that normally drives intestinal peristalsis; vilazodone produces diarrhea through the opposite mechanism of enteric 5-HT1A stimulation, so the two drugs cancel each other's GI effects if coadministered.
C) Vortioxetine's primary GI adverse effect is nausea, which is dose-dependent, typically attenuates over the first one to two weeks of treatment, and can be mitigated by initiating at 5 mg for one week before escalating; vilazodone produces more prominent diarrhea than most SSRIs, which is attributed to its enteric 5-HT1A partial agonism in addition to SERT inhibition and which is more persistent than vortioxetine's nausea.
D) Vilazodone produces nausea as its predominant GI adverse effect because its 5-HT1A partial agonism at gastric vagal afferents triggers the vomiting reflex; vortioxetine produces diarrhea more prominently than nausea because its 5-HT7 antagonism in the colon accelerates transit through a mechanism not shared with other serotonergic antidepressants.
E) Both drugs produce nausea as their primary GI adverse effect, but vortioxetine's nausea is permanent and non-attenuating because its 5-HT3 antagonism prevents the receptor desensitization that would normally reduce nausea over time; vilazodone's nausea attenuates within two weeks through 5-HT1A autoreceptor desensitization at vagal ganglia.
ANSWER: C
Rationale:
Vortioxetine and vilazodone produce different primary GI adverse effects through different mechanisms. Vortioxetine's predominant GI adverse effect is nausea, occurring in approximately 20% to 30% of patients in a dose-dependent manner; it typically attenuates over the first one to two weeks as tolerance develops, and the practical management strategy is to initiate at 5 mg daily for the first week before escalating to the target dose, which reduces the nausea burden during the initiation period. The mechanism is likely related to elevated synaptic serotonin acting on gut receptors. Vilazodone produces more prominent diarrhea than most SSRIs — a more pronounced and persistent GI adverse effect that is the primary driver of early discontinuation in clinical trials. The additional enteric 5-HT1A partial agonism, acting on enteric neurons in addition to SERT inhibition at the gut level, contributes a second pharmacodynamic mechanism at the gastrointestinal tract that conventional SSRIs do not possess, explaining the greater diarrhea severity relative to SSRI comparators. Understanding these mechanistic and clinical differences helps counsel patients about expected GI effects and their time course.
Option A: Option A is incorrect because vortioxetine and vilazodone do not produce identical GI adverse effects through the same mechanism; vortioxetine's primary GI effect is nausea rather than diarrhea, and vortioxetine's additional 5-HT3 and 5-HT7 receptor activities distinguish its enteric pharmacology from vilazodone's 5-HT1A enteric mechanism.
Option B: Option B is incorrect because vortioxetine's primary GI adverse effect is nausea, not constipation; while 5-HT3 antagonism in the gut has anti-nausea and some anti-motility properties at certain receptor locations, vortioxetine does not cause clinically prominent constipation, and the claim that the two drugs' GI effects cancel if coadministered is an oversimplification without clinical basis.
Option D: Option D is incorrect because vilazodone's primary GI adverse effect is diarrhea, not nausea, and vortioxetine does not produce prominent diarrhea through 5-HT7 colonic antagonism; this option reverses the primary GI adverse effects of the two drugs and attributes diarrhea to a 5-HT7 mechanism in the colon that is not established in vilazodone's or vortioxetine's pharmacology.
Option E: Option E is incorrect because vortioxetine's nausea is not permanent and non-attenuating — it typically attenuates over the first one to two weeks; furthermore, the claim that 5-HT3 antagonism prevents receptor desensitization is a pharmacological inversion, since 5-HT3 antagonism would reduce nausea rather than perpetuate it.
9. A US-based psychiatrist is treating a patient with MDD who has responded well to sertraline for mood but continues to have significant sleep-onset insomnia as a residual symptom. The psychiatrist wants to add an agent targeting sleep through a circadian mechanism rather than sedation, and considers agomelatine. A colleague suggests trazodone instead. Integrating mechanism, regulatory status, and practical prescribing considerations, which analysis best justifies the choice between these two agents in the US clinical context?
A) Agomelatine is the preferred choice because its MT1/MT2 agonism directly targets the circadian dysregulation underlying sleep-onset insomnia in MDD, while trazodone's sedation from H1 antagonism is non-specific and does not address circadian pathophysiology; the mechanistically targeted approach justifies its use even in systems where it requires special access.
B) Trazodone and agomelatine are equally appropriate choices; the decision should be based entirely on the patient's preference for the timing and route of administration, since both drugs carry equivalent hepatotoxicity risk and equivalent monitoring burdens that must be discussed with the patient before prescribing.
C) Agomelatine should be chosen over trazodone because it has demonstrated superiority over trazodone in head-to-head randomized controlled trials specifically in patients with MDD and residual sleep-onset insomnia, with significantly greater improvements in sleep latency and next-morning alertness at equivalent doses.
D) Neither agent is appropriate; sertraline should be switched to mirtazapine, which combines H1 antagonism with noradrenergic and serotonergic activity to address both mood and sleep simultaneously, eliminating the need for an augmenting hypnotic agent entirely.
E) Agomelatine is not FDA-approved and is not available in standard US formularies, making it impractical for routine prescribing; trazodone at 50 to 100 mg at bedtime is the more appropriate choice — it is non-scheduled, does not carry dependence risk, improves sleep onset and continuity through H1 antagonism and alpha-1 blockade, and can be added to sertraline without requiring a switch.
ANSWER: E
Rationale:
While agomelatine's MT1/MT2 mechanism offers a theoretically elegant circadian approach to sleep-onset insomnia in MDD, it is not FDA-approved and is not available in standard US pharmacy formularies; a psychiatrist practicing in the United States cannot routinely prescribe it, and obtaining it would require exceptional access pathways not appropriate for routine clinical management. Trazodone at 50 to 100 mg at bedtime is the practical and clinically appropriate choice: it is available, non-scheduled, does not carry physical dependence or respiratory depression risk, and improves sleep onset latency and continuity through potent H1 receptor antagonism and alpha-1 adrenergic blockade — mechanisms that are effective for sleep even if they do not target circadian pathophysiology as specifically as agomelatine would. It can be added to sertraline without a switch and without the mandatory LFT monitoring burden that agomelatine would require even if it were available. In US practice, the clinical niche that agomelatine would occupy in sleep-disrupted MDD is addressed by low-dose trazodone augmentation.
Option A: Option A is incorrect because while the mechanistic reasoning for agomelatine is sound, the practical regulatory reality in the US — that the drug is not FDA-approved and not in standard formularies — is a decisive prescribing consideration that cannot be overridden by mechanistic elegance alone; recommending a drug that cannot be prescribed in the treating clinician's jurisdiction is not clinically actionable.
Option B: Option B is incorrect because trazodone and agomelatine do not carry equivalent hepatotoxicity risks; trazodone has no black-box hepatotoxicity warning and requires no mandatory LFT monitoring, while agomelatine requires a defined monitoring schedule with a discontinuation threshold; describing equivalent risk burdens is pharmacologically and regulatorily inaccurate.
Option C: Option C is incorrect because no head-to-head randomized controlled trials demonstrating agomelatine's superiority over trazodone specifically in US patients with MDD and residual sleep-onset insomnia exist in the pharmacological literature; this claim fabricates a trial-based superiority that has not been established.
Option D: Option D is incorrect because switching sertraline to mirtazapine for a patient with established mood response to sertraline risks destabilizing the mood response; augmenting with a hypnotic agent to address a specific residual symptom without disrupting an effective antidepressant regimen is a more clinically conservative and appropriate strategy.
10. A patient with treatment-refractory depression, hyperlipidemia, and documented failure of four prior antidepressant trials is being considered for nefazodone. His current medications include simvastatin 40 mg nightly, lisinopril, and aspirin. The prescribing physician correctly identifies a serious drug interaction with simvastatin. Which statement correctly identifies the interaction mechanism, the clinical risk, and the appropriate management step before initiating nefazodone?
A) Nefazodone inhibits the hepatic uptake transporter OATP1B1, reducing simvastatin's entry into hepatocytes and paradoxically decreasing statin exposure; the interaction reduces simvastatin efficacy rather than causing toxicity, and the management is to increase the simvastatin dose to 80 mg to compensate for reduced hepatic drug delivery.
B) Nefazodone is a potent CYP3A4 inhibitor; simvastatin is primarily metabolized by CYP3A4, so coadministration markedly increases simvastatin plasma concentrations and raises the risk of statin-induced myopathy and rhabdomyolysis; simvastatin must be switched to a statin not dependent on CYP3A4 metabolism — such as pravastatin or rosuvastatin — before nefazodone is initiated.
C) The interaction is pharmacodynamic rather than pharmacokinetic: nefazodone's 5-HT2A antagonism at skeletal muscle serotonin receptors potentiates the myotoxic effect of statins at normal plasma statin concentrations; the management is to reduce the simvastatin dose to 20 mg and add coenzyme Q10 supplementation to protect mitochondrial function in muscle cells.
D) Nefazodone competes with simvastatin for biliary excretion through the MRP2 transporter, reducing simvastatin's elimination and increasing its systemic exposure; the interaction is clinically significant but manageable through routine creatine kinase monitoring without requiring a statin switch.
E) Nefazodone inhibits CYP2C9, the primary enzyme responsible for simvastatin metabolism; the resulting increase in simvastatin exposure raises rhabdomyolysis risk; switching to atorvastatin — which is metabolized by CYP3A4 rather than CYP2C9 — avoids the interaction entirely.
ANSWER: B
Rationale:
Nefazodone is a potent inhibitor of CYP3A4, and simvastatin is primarily metabolized by CYP3A4 during both intestinal first-pass metabolism and systemic hepatic clearance. Coadministration markedly increases simvastatin plasma concentrations — potentially several-fold — by severely impairing its metabolic clearance. Because statin-induced myopathy and rhabdomyolysis are concentration-dependent toxic effects, the elevated simvastatin levels produced by CYP3A4 inhibition substantially increase skeletal muscle toxicity risk, ranging from myalgia with elevated creatine kinase to life-threatening rhabdomyolysis with acute kidney injury. The correct management before initiating nefazodone is to switch simvastatin to a statin that is not primarily metabolized by CYP3A4. Pravastatin and rosuvastatin are appropriate alternatives: pravastatin undergoes minimal CYP metabolism and rosuvastatin is a minor CYP2C9 substrate with no significant CYP3A4 dependency, making both safe to use with nefazodone. This statin switch must occur before nefazodone is started to prevent the interaction from occurring during the transition period.
Option A: Option A is incorrect because nefazodone inhibits CYP3A4, not the hepatic uptake transporter OATP1B1; furthermore, CYP3A4 inhibition increases rather than decreases simvastatin exposure, making this option wrong on both the mechanism and the direction of the interaction.
Option C: Option C is incorrect because the nefazodone-simvastatin interaction is pharmacokinetic through CYP3A4 inhibition, not pharmacodynamic through serotonin receptor effects on skeletal muscle; there is no established pharmacodynamic interaction between 5-HT2A antagonism and statin myotoxicity at normal plasma concentrations.
Option D: Option D is incorrect because the interaction is CYP3A4-mediated metabolic inhibition, not competition for biliary MRP2 excretion; the MRP2 mechanism is not the basis of this clinically significant interaction, and routine CK monitoring without a statin switch is not appropriate management given the magnitude of the CYP3A4-mediated exposure increase.
Option E: Option E is incorrect because simvastatin is metabolized primarily by CYP3A4, not CYP2C9, so identifying CYP2C9 as the relevant enzyme misidentifies the interaction pathway; furthermore, atorvastatin is also metabolized by CYP3A4 and would be equally affected by nefazodone's CYP3A4 inhibition, making it an inappropriate switch choice.
11. A patient switched from escitalopram to vilazodone develops significant diarrhea during the first two weeks of treatment, despite following the titration schedule and taking the drug with food. She did not experience diarrhea on escitalopram. Her physician explains that the diarrhea is more prominent with vilazodone than with SSRIs for a mechanistic reason. Which explanation integrates vilazodone's pharmacodynamics, the role of the food requirement, and the purpose of the titration schedule most accurately?
A) The diarrhea reflects vilazodone's more potent SERT inhibition compared to escitalopram; because vilazodone inhibits SERT with higher affinity than any available SSRI, it raises enteric serotonin to levels that overwhelm the gut's compensatory mechanisms, producing diarrhea proportional to the degree of SERT occupancy.
B) The diarrhea is an anticholinergic paradox: vilazodone's weak muscarinic agonism at low plasma concentrations activates M3 receptors on intestinal smooth muscle during the titration phase, and the mandatory food coadministration further stimulates gut motility through cholecystokinin release, amplifying the effect until tolerance develops.
C) The diarrhea occurs because vilazodone inhibits P-glycoprotein efflux transporters in the intestinal wall, reducing enterocyte secretion of bile acids back into the gut lumen; the accumulation of bile acids in the colon produces osmotic diarrhea that persists until P-glycoprotein expression is upregulated adaptively after several weeks of drug exposure.
D) Vilazodone produces more prominent diarrhea than SSRIs because its 5-HT1A partial agonism acts on enteric neurons in addition to SERT inhibition at the gut level, contributing a second pharmacodynamic mechanism to gastrointestinal adverse effects that SSRIs lack; mandatory food coadministration and the stepwise titration schedule both reduce but do not eliminate this effect, and patients should be counseled that diarrhea typically attenuates over the first weeks of treatment.
E) The diarrhea is entirely explained by the mandatory food requirement: the high-calorie meals required to achieve adequate vilazodone bioavailability increase intestinal osmotic load and accelerate gastric emptying through gastrocolic reflex activation; patients who switch to lower-fat meals that still meet the minimum caloric threshold for absorption experience resolution of diarrhea without any change in drug dose.
ANSWER: D
Rationale:
Vilazodone produces more prominent diarrhea than most SSRIs because it combines two pharmacodynamic mechanisms at the gastrointestinal level: SERT inhibition, which raises enteric serotonin and activates pro-motility serotonin receptors in the enteric nervous system as SSRIs also do, and 5-HT1A partial agonism at enteric 5-HT1A receptors on gut neurons, a second mechanism that SSRIs lack entirely. This dual enteric pharmacodynamic action drives the greater diarrhea burden compared to escitalopram and other pure SERT inhibitors. The mandatory food coadministration requirement partially mitigates GI adverse effects — taking the drug in a fed state slows absorption and reduces peak plasma concentrations — but does not eliminate them because the enteric receptor activity persists regardless. The stepwise titration schedule (10 mg → 20 mg → 40 mg over two weeks) is specifically designed to minimize early GI adverse effects by allowing gradual adaptation of enteric receptor populations before reaching the target dose. Patients should be counseled that diarrhea is expected to attenuate over the first weeks of treatment as enteric receptor adaptation occurs.
Option A: Option A is incorrect because vilazodone's SERT inhibitory potency is comparable to that of sertraline and escitalopram — not substantially higher — and the greater diarrhea is not explained by superior SERT affinity but by the addition of enteric 5-HT1A partial agonism that SSRIs lack.
Option B: Option B is incorrect because vilazodone does not have muscarinic agonism at M3 receptors; vilazodone's pharmacological profile is defined by SERT inhibition and 5-HT1A partial agonism, with no meaningful muscarinic activity, and the food requirement is a bioavailability consideration, not a cholecystokinin-mediated motility amplifier.
Option C: Option C is incorrect because vilazodone does not inhibit P-glycoprotein in the intestinal wall, and the bile acid osmotic diarrhea mechanism described is not part of vilazodone's established pharmacological profile; this option fabricates an entirely unsupported transporter-mediated mechanism.
Option E: Option E is incorrect because vilazodone's food requirement is a bioavailability concern related to drug absorption rather than a caloric-load-driven osmotic effect; the diarrhea is a pharmacodynamic adverse effect of the drug at the enteric receptor level, not a consequence of meal composition or the gastrocolic reflex from high-calorie food intake.
12. A patient with Child-Pugh class B hepatic cirrhosis is seen for major depressive disorder. A medical student asks why agomelatine is absolutely contraindicated in hepatic impairment. The supervising physician explains that two independent pharmacological reasons converge on the same contraindication. Which answer correctly identifies both reasons?
A) First, agomelatine causes hepatotoxicity in a subset of patients through its metabolite's effects on hepatic mitochondria, and initiating a hepatotoxic drug in a patient with pre-existing hepatic impairment removes the safety margin needed to detect and respond to further liver injury; second, agomelatine undergoes extensive first-pass hepatic metabolism producing a baseline bioavailability of only 3% to 5%, so severe hepatic impairment dramatically increases bioavailability and plasma concentrations to unpredictably high and potentially toxic levels.
B) First, agomelatine is contraindicated because CYP1A2 — its primary metabolic enzyme — is exclusively expressed in hepatocytes and is absent in cirrhotic liver tissue regardless of the degree of impairment; second, the melatonin receptors that agomelatine targets are expressed on hepatic stellate cells, meaning the drug directly activates hepatic stellate cells in cirrhotic livers and accelerates fibrosis progression.
C) First, agomelatine accumulates in hepatic tissue at concentrations 40 to 60 times higher than plasma due to high hepatic extraction, so any hepatic impairment allows this sequestered drug to re-enter systemic circulation and produce supratherapeutic plasma concentrations; second, agomelatine's 5-HT2C antagonism on hepatic Kupffer cells impairs their phagocytic function, increasing susceptibility to hepatic infections in cirrhotic patients.
D) First, agomelatine is a direct hepatotoxin that damages hepatocytes through covalent protein binding at therapeutic plasma concentrations, making any degree of hepatic impairment an absolute contraindication; second, the contraindication is reinforced because agomelatine cannot be monitored with standard liver function tests in cirrhotic patients because baseline transaminase elevation in cirrhosis prevents detection of drug-induced superimposed injury.
E) First, agomelatine requires conversion to its active form by CYP1A2 in the liver, and hepatic impairment prevents this bioactivation, rendering the drug completely inactive; second, the inactive parent compound accumulates in hepatic impairment and undergoes spontaneous hydrolysis to a nephrotoxic metabolite, adding renal failure risk to the hepatic concern.
ANSWER: A
Rationale:
Two independent pharmacological reasons converge to make agomelatine absolutely contraindicated in hepatic impairment. The first is the hepatotoxicity risk itself: agomelatine causes liver enzyme elevations in approximately 1% to 3% of patients and rare cases of symptomatic hepatitis and hepatic failure. Prescribing a drug with established hepatotoxic potential in a patient with pre-existing liver disease removes the safety margin needed to monitor for and respond to drug-induced liver injury — any further elevation of transaminases cannot be clearly attributed to the drug versus the underlying liver disease, and the threshold for discontinuation is more difficult to interpret. The second reason is pharmacokinetic: agomelatine undergoes extensive first-pass hepatic metabolism, producing an average bioavailability of only approximately 3% to 5% in patients with normal liver function. In a patient with significant hepatic impairment such as Child-Pugh class B cirrhosis, the reduced first-pass metabolic capacity dramatically increases agomelatine bioavailability — potentially from the low single-digit percentage range to much higher levels — producing unpredictably elevated plasma concentrations at standard doses and increasing both hepatotoxicity risk and systemic adverse effects. These two reasons are independent: each alone would be sufficient justification for the contraindication, but together they make use in hepatic impairment unacceptable.
Option B: Option B is incorrect because CYP1A2 is not exclusively expressed in hepatocytes and is not absent in all cirrhotic tissue; enzyme expression is reduced but not eliminated in most cases of hepatic impairment, and the claim that agomelatine activates hepatic stellate cells through MT1/MT2 receptors to accelerate fibrosis is pharmacologically unsupported.
Option C: Option C is incorrect because agomelatine does not accumulate in hepatic tissue at concentrations 40 to 60 times higher than plasma, and the mechanism described — hepatic sequestration followed by re-release in impairment — is not the established pharmacokinetic explanation for the contraindication; additionally, 5-HT2C antagonism impairing Kupffer cell phagocytic function is not an established adverse effect of agomelatine.
Option D: Option D is incorrect because agomelatine is not a direct hepatotoxin at therapeutic plasma concentrations through covalent protein binding; its hepatotoxicity is idiosyncratic and occurs in a small subset of patients, not universally, and standard liver function monitoring in cirrhotic patients, while more complex to interpret, is not impossible.
Option E: Option E is incorrect because agomelatine is not a prodrug requiring bioactivation by CYP1A2; it is pharmacologically active in its administered form, and the claim that it undergoes spontaneous hydrolysis to a nephrotoxic metabolite in hepatic impairment fabricates a metabolic pathway without pharmacological basis.
13. A 38-year-old woman with recurrent major depressive disorder discontinued sertraline after six months of adequate mood response because of intolerable sexual dysfunction. She works rotating shifts and frequently cannot predict whether she will eat before taking a morning medication. She has no insomnia complaint and no hepatic disease. Her psychiatrist wants to prescribe one of the five agents from this module. Integrating the pharmacological profiles across all five agents, which choice is best supported and why?
A) Vilazodone, because its 5-HT1A partial agonism is associated with a more favorable sexual dysfunction profile than sertraline, and its antidepressant efficacy is well-established; the food requirement is manageable with patient education, and the rotating shift schedule does not affect the drug's pharmacodynamics.
B) Agomelatine, because its MT1/MT2 mechanism directly targets circadian dysregulation that is common in rotating shift workers, addressing both the mood disorder and the disrupted sleep-wake cycle simultaneously; its absence of monoamine transporter activity avoids the sexual dysfunction that ended her sertraline treatment.
C) Vortioxetine, because its bioavailability of approximately 75% is unaffected by food — eliminating the meal-timing adherence variable that would complicate vilazodone use — and clinical trial data demonstrate rates of sexual dysfunction comparable to placebo, directly addressing the adverse effect that caused her sertraline discontinuation.
D) Trazodone, because its alpha-1 adrenergic blockade in the penile vasculature does not apply to female patients, making it free of sexual adverse effects in women; its once-nightly dosing schedule avoids the meal-timing problem, and its 5-HT2A antagonism preserves REM sleep architecture that may be disrupted by her shift work.
E) Nefazodone, because it preserves REM sleep architecture that may be disrupted by rotating shift work, and its 5-HT2A antagonism does not produce the postsynaptic 5-HT2-mediated sexual dysfunction associated with SSRIs; for a patient who has already failed sertraline, its risk-benefit profile is acceptable given the treatment history.
ANSWER: C
Rationale:
Vortioxetine is the best-supported choice when the three key clinical constraints are integrated systematically. First, the irregular meal schedule: vortioxetine has an oral bioavailability of approximately 75% that is unaffected by food, meaning it can be taken without regard to meals without compromising drug exposure — a critical practical advantage over vilazodone, whose bioavailability falls from 72% with food to 47% in the fasted state, and which would be unreliable in a patient who cannot predict meal timing. Second, the sexual dysfunction: clinical trial data using prospective sexual function assessment instruments demonstrate that vortioxetine produces rates of sexual dysfunction comparable to placebo, making it the agent in this module with the strongest evidence base for favorable sexual effects — directly relevant to a patient whose prior antidepressant discontinuation was driven by this adverse effect. Third, the absence of an insomnia complaint means the sedating properties of trazodone provide no benefit and would add unnecessary daytime sedation risk; the hepatotoxicity risk of nefazodone or agomelatine monitoring burdens are unjustified in a patient with no hepatic disease and available safer alternatives.
Option A: Option A is incorrect because vilazodone's food requirement is a clinically significant prescribing constraint for this patient specifically; its sexual dysfunction advantage over SSRIs is less robustly established than vortioxetine's, and the meal-timing problem is not merely manageable with education when the patient's irregular shift schedule makes consistent food coadministration structurally unpredictable.
Option B: Option B is incorrect because agomelatine is not FDA-approved in the United States and is not available in standard US formularies; while the circadian rationale for shift workers is pharmacologically sound, it is clinically irrelevant if the drug cannot be prescribed in the treating clinician's practice setting, and the mandatory LFT monitoring burden adds complexity without indication.
Option D: Option D is incorrect because trazodone at hypnotic doses is primarily prescribed for insomnia, which this patient does not have; using a sedating hypnotic as a stand-alone antidepressant at doses sufficient for mood effect would require 300 to 600 mg daily with significant sedation and orthostatic hypotension, and the rotating shift schedule makes a sedating drug particularly problematic.
Option E: Option E is incorrect because nefazodone is reserved for refractory depression after failure of multiple adequate antidepressant trials; this patient has failed one antidepressant for an adverse effect reason, not for inadequate efficacy after adequate duration, which does not meet the threshold at which nefazodone's hepatotoxicity risk becomes an acceptable trade-off.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.